Tardive dyskinesia is not associated with the polymorphisms of 5-HT2A receptor gene, serotonin transporter gene and catechol-o-methyltransferase gene

European Psychiatry

Volumn 18, Issue 2, 2003, Pages 77-81

  Herken, Hasan ^a   Erdal, M Emin ^b   Böke, Ömer ^c   Savaş, Haluk A ^a  

^a GAZIANTEP UNIVERSITY   (Turkey)

^b MERSIN UNIVERSITY   (Turkey)

^c Samsun Mental Health and Diseases Hospital   (Turkey)

Author keywords

5 HTT gene; 5 HT2A receptor gene; COMT gene; Schizophrenia; Tardive dyskinesia

Indexed keywords

CATECHOL METHYLTRANSFERASE; NEUROLEPTIC AGENT; SEROTONIN 2A RECEPTOR; SEROTONIN TRANSPORTER;

ADULT; CONFERENCE PAPER; CONTROLLED STUDY; EVALUATION; FEMALE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECEPTOR GENE; SCHIZOPHRENIA; STATISTICAL SIGNIFICANCE; TARDIVE DYSKINESIA;

EID: 0037628614     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-9338(03)00005-1     Document Type: Conference Paper

References (39)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington (DC): APA; 1994.
2. Arkonaç O. Turkish version of extrapyramidal symptoms rating scale (ESRS). In: Aydemir O, Koroglu E, editors. Psikiyatride kullanilan klinik olcekler (translation: clinical scales used in psychiatry). Ankara: Hekimler yayin birligi. 2000. p. 88-92.
3. Arranz MJ, Munro J, Owen MJ, Spurlock G, Sham PC, Zhao J, et al. Evidence for association between polymorphism in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine. Mol Psychiatry 1998;3:61-6.
4. Basile VS, Masellis M, Badri F, Paterson AD, Meltzer HY, Lieberman JA, et al. Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia. Neuropsychopharmacology 1999;21:17-27.
5. Basile VS, Ozdemir V, Masellis M, Walker ML, Meltzer HY, et al. A functional polymorphism of the cytochrome P450. A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia. Mol Psychiatry 2000;1(;5):410-7.
6. Basile VS, Ozdemir V, Masellis M, Meltzer HY, Lieberman JA, Potkin SG, et al. Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia. Mol Psychiatry 2001;6:230-4.
7. Casey DE. Neuroleptic-induced extrapyramidal syndromes and tardive dyskinesia. In: Hirsch S, Weinberger DR, editors. Schizophrenia. Oxford (UK): Blackwell; 1995. p. 546-65.
8. Chen CH, Wei FC, Koong FJ, Hsiao KJ. Association of Taq I polymorphism of dopamine D2 receptor gene and tardive dyskinesia in shizophrenia. Biol Psychiatry 1997;41:827-9.
9. Chouinard G, Ross-Chouinard A. Extrapyramidal Rating Scale (ESRS). Montreal: The Autors; 1984.
10. Ellingrod VL, Schultz SK, Amdt S. Association between cytochrome P450. D6 (CYP2D6) genotype antipsychotic exposure, and abnormal involuntary movement scale (AIMS) score. Psychiatry Genet 2000;2(10):9-11.
11. Guala A, Mittino D, Ghini T, Quazza G. Are metoclopramide dystonias familial?. Pediatr Med Chir 1992;14:617-8.
12. Herken H, Uz E, Özyurt H, Söǧüt S, Virit O, Akyol Ö. Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia. Mol Psychiatry 2001;6:66-73.
13. Hori H, Ohmori O, Shinkai T, Kojima H, Okano C, Suzuki T, et al. Manganese superoxide dismutase gene polymorphism and schizophrenia: relation to tardive dyskinesia. Neuropsychopharmacology 2000;23:170-7.
14. Hu S, Brody CL, Fisher C, Gunzerath L, Nelson ML, Sabol SZ, et al. Interaction between the serotonin transporter gene and neuroticism in cigarette smoking behavior. Mol Psychiatry 2000;5:181-8.
15. Jeste DV, Caligiuri MP. Tardive dyskinesia. Schizophr Bull 1993;19:303-15.
16. Karayiorgou M, Altemus M, Galke BL, Goldman D, Murphy DL, Ott J, et al. Genotype determining low catechol-O-methyltransferase activity as a risk factor for obsessive-compulsive disorder. Proc Natl Acad Sci USA 1997;94:4572-5.
17. Kalow W, Tang BK. Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther 1991;50:508-19.
18. Kalow W, Tang BK, Endrenyi L. Hypothesis: comparison of inter and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics 1998;8:283-9.
19. Kalow W, Tang BK. Caffeine as a metabolic probe: exploration of enzyme-inducing effect of cigarette smoking. Clin Pharmacol Ther 1991;49:44-8.
20. Kirch DG, Alho AM, Wyatt RJ. Hypothesis: a nicotine-dopamine interaction linking smoking with Parkinson's disease and tardive dyskinesia. Cell Mol Neurobiol 1988;8:285-91.
21. Macciardi F, Verga M, Cavallaro R, Pedrini S, Cohen S, Smeral di E. A genetic study of tardive dyskinesia in an İtalian population of chronic schizophrenics. Proceeding of World Congress on Psychiatric Genetics, San Francisco, Psychiatric Genetics; 1996.
22. Miller M, Opheim KE, Raisys VA, Motulsky AG. Teophylline metabolism: variation and genetics. Clin Pharmacol Ther 1984;35:170-82.
23. Rosengarten H, Schweitzer JW, Friedhoff AJ. Possible genetic factors underlying the pathophysiology of tardive dyskinesia. Pharmacol Biochem Behav 1994;49:663-7.
24. Rosengarten H, Schweitzer JW, Friedhoff AJ. A mechanism underlying neuroleptic-induced oral dyskinesias in rats. Pol J Pharmacol 1993;45:391-8.
25. Rosengarten H, Schweitzer JW, Friedhoff AJ. A sub population of the dopamine D1 receptors mediate repetetive jaw movements in rats. Pharmacol Biochem Behav 1993;45:921-4.
26. Sachdev PS. The current status of the tardive dyskinesia. Aust New Zealand J Psychiatry 2000;34:355-69.
27. Saltz BL, Kane JM, Woerner MG, Lieherman JA, Alvir JJ. Aging and tardive dyskinesia. In: Yassa R, Nair NPV, Jeste DV, editors. Neuroleptic-induced movement disorders. New York: Cambridge University Press; 1997. p. 13-25.
28. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiat 1982;39:486-7.
29. Segman RH, Heresco-Levy U, Finkel B, Goltser T, Shalem R, Schlafman M, et al. Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 2001;6:225-9.
30. Strous RD, Bark N, Woerner M, Lachman HM. Lack of association of a functional catechol-O-methyltransferase gene polymorphism in schizophrenia. Biol Psychiatry 1997;41:493-5.
31. Swartz JR, Burgoyne K, Smith M, Gadasaly R, Ananth J, Anantk K. Tardive dyskinesia and ethnicity: review of the literature. Ann Clin Psychiatry 1997;9:53-9.
32. Tsai G, Goff DC, Chang RW, Flood J, Baer L, Coyle JT. Markers of glutamaterjic neurotransmission and oxidative stress associated with tardive dyskinesia. Am J Psychiatry 1998;155:1207-13.
33. Tut GT, Wang JL, Lim CCL. Negative association between T102C polymorphism at the 5-HT2A receptor gene and bipolar affective disorders in Singaporen Chinese. J Affect Dis 2000;58:211-4.
34. O'Callaghan E, Larkin C, Kinsella A, Waddington JL. Obstetric complications, the putative familial-sporadic distinction, and tardiv dyskinesia in schizophrenia. Br J Psychiatry 1990;157:578-84.
35. Ohmori O, Suzuki T, Kojima H, Shinkai T, Terao T, Mita T, et al. Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics. Schizophrenia Research 1998;32:107-13.
36. Waddington JL, Youssef HA. The expression of schizophrenia, affective disorder, and vulnerability to tardive dyskinesia in an extensive pedigree. Br J Psychiatry 1988;153:376-81.
37. Yamada K, Kanba S, Anamizu S, Ohnichi K, Ashikari J, Yagi G, et al. Low superoxide dismutase in schizophrenic patients with tardive dyskinesia. Psychol Med 1997;27:1223-5.
38. Yassa R, Lal S, Korpassy A, Ally J. Nicotine exposure and tardive dyskinesia. Biol Psychiatry 1987;22:67-72.
39. Yilmaz M, Erdal ME, Herken H, Çataloluk O, Barlas Ö, Bayazit Y. Significance of the serotonin transporter gene polymorphism in migraine. J Neurological Sci 2001;186:27-30.